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Hearing loss in Fabry disease: data from the Fabry Outcome
Survey
Abstract
Hearing loss is a common symptom in Fabry disease, but neither its natural course nor its aetiology has
been defined precisely. The aim of this study was to provide a detailed epidemiological description of
hearing impairment in patients in the Fabry Outcome Survey (FOS), which is the largest available
database of Fabry patients. Questionnaires were completed by 566 Fabry patients, of whom 316 reported
ear-related symptoms. Pure-tone audiograms from 86 patients, performed before starting enzyme
replacement therapy, were analysed and compared with age- and sex-specific normal values
(International Organization for Standardization, ISO 7029). When compared to an age-matched
population (ISO 7029), 74% of patients had a threshold elevated above the 95th centile in at least one
tested frequency. All frequencies were affected to a similar degree. However, only 14 patients (16%)
were clinically affected by hearing impairment according to the age-independent World Health
Organization (WHO) classification (mean threshold at 0.5, 1 and 2 kHz worse than 25 dB). Hearing loss
was sensorineural in 63 patients (73%) of whom 7 patients (8%) had also a conductive component. One
patient had a purely conductive hearing loss. Episodes of sudden hearing loss seemed to occur more
frequently than in the general population. Men were affected earlier and more severely than women.
Hearing in Fabry disease is significantly worse than in an age-matched general population but leads to
clinically relevant hearing impairment in only 16% of cases. It resembles accelerated presbycusis with
an additional Fabry-specific strial-type hearing loss.
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Abstract Background
 
Hearing loss is a common symptom in Fabry disease, but neither its natural
course nor its aetiology has been defined precisely. The aim of this study was to provide a
detailed epidemiological description of hearing impairment in patients in the Fabry Outcome
Survey (FOS), which is the largest available database of Fabry patients.
 
Materials and methods
 
Questionnaires were completed by 566 Fabry patients, of whom
316 reported ear-related symptoms. Pure-tone audiograms from 86 patients, performed
before starting enzyme replacement therapy, were analysed and compared with age- and
sex-specific normal values (International Organization for Standardization, ISO 7029).
 
Results
 
When compared to an age-matched population (ISO 7029), 74% of patients had
a threshold elevated above the 95th centile in at least one tested frequency. All frequencies
were affected to a similar degree. However, only 14 patients (16%) were clinically affected
by hearing impairment according to the age-independent World Health Organization (WHO)
classification (mean threshold at 0·5, 1 and 2 kHz worse than 25 dB). Hearing loss was
sensorineural in 63 patients (73%) of whom 7 patients (8%) had also a conductive
component. One patient had a purely conductive hearing loss. Episodes of sudden hearing
loss seemed to occur more frequently than in the general population. Men were affected
earlier and more severely than women.
 
Conclusions
 
Hearing in Fabry disease is significantly worse than in an age-matched general
population but leads to clinically relevant hearing impairment in only 16% of cases. It
resembles accelerated presbycusis with an additional Fabry-specific strial-type hearing loss.
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Introduction
 
Fabry disease (FD) is an X-linked lysosomal storage
disease, affecting almost all organs with deposition of
glycosphingolipids, mainly globotriaosylceramide (Gb3).
Since the development of enzyme replacement therapy
(ERT) with the deficient enzyme 
 
α
 
-galactosidase A (
 
α
 
-GAL),
there has been increased interest in both the pathophysiology
and therapy of FD. A common and often worrying, though
not life-threatening, symptom in Fabry patients is hearing
loss. However, neither the natural course of hearing function
in these patients nor its aetiology has been established in
detail.
Histopathological findings in the temporal bone have
been reported in only two patients [1]. The authors found
abnormalities in the middle and inner ear that could
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theoretically cause severe hearing and vestibular symptoms.
They described hyperplastic squamous epithelium, muco-
periostal thickening and fibrosis with seropurulent effusion
in the middle ear, atrophy of the stria vascularis and spiral
ligament, moderate loss of outer hair cells and mild cochlear
hydrops in the apical turn. Spiral ganglion cells were
decreased in number but otherwise normal with no signs
of lipid storage. In addition they found haemorrhage in the
saccule, hyperostosis filling the perilymphatic space of the
semicircular canals and ballooning of Scarpa’s ganglion
cells with granulating nuclei as well as accumulation of Gb
 
3
 
.
Glycosphingolipids were also seen in vascular endothelial
cells, leading to markedly distorted vessels.
Epidemiological data on hearing loss in FD are rare.
Besides anecdotal reports, only a few previous studies have
investigated the natural course of hearing loss. MacDermot
 
et al
 
. described self-reported hearing loss in 23% of 60
heterozygous women [2] and in 41% of 61 hemizygous men
[3]. In 23 of the male patients, audiograms were performed,
of which 73% were deemed ‘abnormal’. Hearing has been
investigated more specifically in three small studies of 22
[4], 14 [5] and 15 [6] patients with FD. These three groups
found that high-frequency sensorineural hearing loss
(SNHL) was the predominant abnormality. In addition,
Germain 
 
et al
 
. [5] and Conti and Sergi [4] found a high
incidence of sudden onset or progression of hearing loss.
Neither study found any evidence of retrocochlear pathology
with brainstem audiometry. This is consistent with the
normal appearance of ganglion cells found by Schachern
 
et al
 
. [1]. Hajioff 
 
et al
 
. reported on three patients (13%) with
conductive hearing loss due to middle ear effusion [6]. One
small study found no hearing loss on pure-tone audiometry
in six children with FD, but four had non-troublesome
tinnitus [7].
The Fabry Outcome Survey (FOS) is a multi-centre study
designed to collect data on Fabry patients in a systematic
fashion to allow detailed description of functional impair-
ments and to assess the effect of ERT on affected organ
systems. The present study set out to use the pre-treatment
data in FOS, which is the largest database on patients with
FD, to produce a detailed epidemiological description of
hearing function in affected patients.
 
Materials and methods
 
FOS database
 
Sixty collaborating centres from 11 countries contributed
to the database (Germany, 23%; UK, 14%; Czech Republic,
11%; Switzerland, 10%; Italy, 9%; Spain, 8%; France, 7%;
Belgium, 6%; Norway, 5%; Sweden, 4%; Austria, 3%). All
of them are university hospitals or other tertiary referral
centres for audiological patients. Medical histories were
taken by FOS investigators using a standardized question-
naire. Patients were asked whether they had experienced
subjective hearing loss, sudden hearing loss, vertigo or
tinnitus. Data were depersonalized and entered into an
internet-based database. The Ethics Committee or Institu-
tional Review Board of all participating centres approved
FOS and all patients gave written informed consent. The
FOS database and its properties have been described
elsewhere [8].
As of November 2004, 638 patients with FD were
included in the database. The diagnosis was confirmed in
all patients by enzyme assay or DNA analysis. A medical
history, based on the questionnaire, was available for 566
patients (267 females [47%], mean age 39 years, range 2–
76 years, and 299 males [53%], mean age 34 years, range
1–69 years). Of these, 316 (56%) reported at least one ear-
related symptom in the form of hearing loss (32%), tinnitus
(30%) or dizziness (30%).
Pure-tone audiograms have been obtained from 86
patients (47 females, 39 males) before starting ERT. The
audiograms have been taken at 10 centres in the UK,
Germany, Switzerland, Italy, France, Norway and Spain.
 
Hearing loss
 
Each patient underwent otoscopy before audiological testing.
Pure-tone audiograms with air conduction thresholds at
0·25, 0·5, 1, 2, 4 and 8 kHz were performed in a quiet room
by experienced audiologists, with bone conduction thresh-
olds and masking as appropriate. All centres followed the
guidelines of ISO 8253–1 (International Organization
for Standardization [1989]. Acoustics – Audiometric test
methods – Part 1: Basic pure tone air and bone conduction
threshold audiometry. http://www.iso.org), which is obligatory
in the EU and Switzerland.
Hearing thresholds were considered normal if they were
better than or equal to the age-specific 95th centile of
the normal population in ISO 7029 (International Institute
for Standardization, ISO 7029 [9]). An air-bone gap was
defined as an average air conduction threshold (at 0·5, 1
and 2 kHz) that was 15 dB or more above the bone con-
duction threshold.
To assess the clinical relevance of the audiometric data
and to categorize the degree of hearing impairment, we
used age-independent clinical guidelines according to the
international classification of impairments, disabilities
and handicaps [10]. Averages for pure-tone audiometric
thresholds (PTA) at 0·5, 1 and 2 kHz were classified as
normal (0–25 dB PTA), mild (26–40 dB PTA), moderate
(41–55 dB PTA), moderately severe (56–70 dB PTA),
severe (71–90 dB PTA) or profound (> 90 dB PTA). Our
methods are comparable to those used by Germain 
 
et al
 
.
[5].
Furthermore, audiogram configurations were classified
according to the criteria of Mazzoli 
 
et al
 
. [11] as follows:
 
1
 
Low-frequency loss, ascending: the difference between
the poorer low frequencies and the high frequencies
exceeded 15 dB.
 
2
 
Mid-frequency ‘U’-shaped loss: the difference between
the poorer mid frequencies and the better high and low
frequencies exceeded 15 dB.
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3
 
High-frequency loss, gently sloping: a 15–29 dB
difference between the mean thresholds at 500 and
1000 Hz and the mean at 4 and 8 kHz.
 
4
 
High-frequency loss, steeply sloping: a 30 dB or greater
difference between the mean thresholds at 500 and
1000 Hz and the mean at 4 and 8 kHz.
 
5
 
Flat: the difference between the mean thresholds at 250
and 500 Hz and at 4 and 8 kHz did not exceed 15 dB.
We excluded normal audiograms, which we defined as
those in which all thresholds were no worse than 20 dB. All
authors classified the audiogram shapes independently and
discussed the small number in which classifications were
initially discordant.
Finally, audiograms from both ears of each patient were
compared and classified as bilateral symmetric, bilateral
asymmetric or unilateral. The criterion for asymmetry was
an interaural threshold difference of more than 15 dB in two
adjacent frequencies. Conductive hearing loss was not
encountered. Again, normal audiograms were excluded
(based on the same criteria above).
 
Sudden hearing loss
 
Sudden sensorineural hearing loss (SSNHL) has been
defined as a sensorineural hearing loss of 30 dB or more at
three or more adjacent frequencies occurring within three
days [12]. This definition could not be applied meaningfully
to our database, as audiometric data around the time of the
suspected SSNHL were not available. Therefore, we used
the occurrence of a subjective significant hearing loss
within three days as a criterion for sudden hearing loss. To
distinguish this from objective SSNHL, the reported
sudden hearing loss will be referred to as SHL. We compared
the incidences of SHL in our Fabry population with
age- and sex-matched incidences in a general population
reported in a Japanese survey in 1993 [13].
 
Results
 
Hearing thresholds were not worse than 20 dB in any
frequency bilaterally in 43 of 86 patients (50%). In the
other half, hearing loss was bilateral and symmetric in 25
cases, bilateral and asymmetric in 6 cases, and unilateral
in the remaining 12 cases. However, when compared
with ISO 7029 hearing was normal in only 26% of
patients (Fig. 1), in 30% of females and in 21% of males. The
difference between sexes was not significant (
 
P =
 
 0·33).
Hearing loss was most often sensorineural (63 patients,
73%). In seven of these cases (8%, 2 female, 5 male)
hearing loss was mixed. A purely conductive hearing loss
was found unilaterally in one female patient only. We could
not determine from the database the cause or duration of
these conductive hearing losses and, because of the small
number of patients, we have not analysed conductive hearing
losses further.
 
Hearing loss – age-matched
 
Baseline hearing thresholds in all patients (172 ears) are
plotted for each frequency in Fig. 2 in relation to the 50th
and 95th centiles of age- and sex-dependent hearing levels
in the general population according to ISO 7029. With
conductive (
 
n
 
 = 1) or mixed (
 
n
 
 = 7) hearing loss, bone
conduction levels have been plotted; otherwise (
 
n
 
 = 78) air
conduction thresholds are used. We did not find a significant
difference between left and right ears (paired 
 
t
 
-test,
 
P
 
 > 0·5). There is an obvious difference between sexes
where the elevated thresholds in men are on average further
from the 95th centile. There are also very few data points
at or below the 50th centile especially at 8 kHz.
Compared with the ISO 7029 age-matched thresholds,
only 65 of 172 ears (38%) had normal hearing levels on
baseline pure-tone audiometry at all frequencies (Fig. 3). If
an elevated threshold at only one frequency was accepted
as normal, 55% of the patients could be classified as having
normal hearing. However, 99% of all ears were above the
50th centile in at least three frequencies and 100 ears (58%)
were above this median value in all frequencies. Thus, no
patient had hearing consistently better than the median of
a reference population. The better than average thresholds
only occur at or above 1 kHz.
Looking at the relative numbers of pathological thresholds
(above the 95th centile) (Fig. 4), it appears that at any of
the tested frequencies about 40–50% of the patients have
pathological thresholds. Lower frequencies seem to be
Figure 1 Occurrence of different types of hearing loss in (a) all 
ears (n = 172) and (b) worse ear of each individual patient with 
Fabry disease (n = 86).
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affected slightly more than higher frequencies but that is not
statistically significant. The percentage of thresholds between
the 50th and 75th centiles and between the 75th and 95th
centiles increased in the Fabry population towards the
higher frequencies. In general, hearing in Fabry patients
resembles the age-related hearing loss in a normal popu-
lation but starts earlier and progresses faster. Male patients
had more severe hearing loss than female patients (Fig. 1).
Figure 2 Individual hearing thresholds of all ears of female (left-hand panels) and male (right-hand panels) patients with Fabry disease 
at baseline pure-tone audiometry (before the start of enzyme replacement therapy) at different frequencies. The solid lines represent the 
50th centile and the dotted line the 95th centile of an age- and sex-matched general population according to the International Organization 
for Standardization (ISO 7029). Hearing thresholds apparently lay outside the normal range to approximately the same amount in all 
frequencies. In men thresholds lie clearly more often above the 95th centile and also have a greater distance to that line as compared to 
women. There is no evident difference between right and left ears.
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Hearing impairment – age-independent
 
An elevated threshold in one or two frequencies might not
be of clinical importance for the patient. Therefore, we
evaluated the hearing impairment according to the WHO
guidelines for the classification of impairments, disabilities
and handicaps, which better reflects the functional impair-
ment in an age-independent manner. This reveals a quite
different picture (Fig. 5). Regarding the worse ear of each
patient only, 84% of patients were classified as normal, 12%
as having a mild hearing impairment and only 4% as having
a moderate or severe hearing impairment (2% each).
 
Audiogram configuration
 
From the audiogram configuration for each of the 172
tested ears, 95 (55%) could be classified as normal, 42
Figure 2 (continued)
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(24%) as flat, including 2 (1%) deaf ears, 21 (12%) as gently
sloping high-frequency hearing loss and 12 (7%) as steeply
sloping hearing loss. Low-frequency ascending and mid-
frequency U-shaped audiograms were seen in only one ear
each. Note that a sloping audiogram is the typical con-
figuration for age-related hearing impairment and cannot
necessarily be linked to FD. These results are in accordance
with our analysis of individual age-related thresholds that
also revealed involvement of all frequencies. The low-
frequency ascending and the U-shaped audiograms, which
could be suspect for cochlear hydrops, were detected in two
ears only.
 
Sudden hearing loss
 
At least one episode of SHL was reported by 9 of 267
(3·4%) women (mean age 38·0 years, range 6·8–65·2 years)
and by 23 of 299 (7·7%) men (mean age 37·1 years, range
14·9–54·4 years). Thus, 32 cases of SHL (5·6%) were found
in the 566 patients with a complete symptom checklist.
At the time of reporting, audiograms were available from
15 patients with SHL, with a mean age of 43 years (females
44 years, males 42 years), ranging between 28 and 66 years
(females 28–66 years, males 33–54 years).
Six of the audiograms from the SHL patients were taken
before the start of ERT. Four of these audiograms showed
an asymmetry between right and left ears. As bilateral
symmetric sudden hearing losses are rare (2%) [13], we
Figure 3 Hearing loss in patients with Fabry disease as compared 
with an age-matched general population (International 
Organization for Standardization, ISO 7029). The percentages of 
patients with thresholds below the 50th centile or above the 50th, 
75th and 95th centile of ISO 7029 are shown. While thresholds 
below the 50th centile cannot possibly be observed when this 
centile is close to zero, it is not surprising that such thresholds 
can only be seen at the frequencies above 1 kHz. Note that the 
percentage of pathological thresholds (> 95th centile) is between 
40 and 50% at all frequencies in the worst ear. (a) All ears and 
(b) Worse ear of each patient.
Figure 4 Numbers of thresholds in (a) all ears and (b) worse ear 
of each Fabry patient elevated above the 95th and 50th centiles; 
65 (38%) of all ears but only 22 (26%) of the worst ear of each 
patient have a normal threshold at all frequencies. There is no ear 
with all thresholds better than the 50th centile and all but two lie 
in at least three frequencies above the normal median.
Figure 5 Hearing impairment in patients with Fabry disease 
according to the international classification of impairments, 
disabilities and handicaps (World Health Organization (WHO), 
May 1980, Geneva, Switzerland). Severity is determined by the 
pure-tone average of 0·5, 1 and 2 kHz of the worse ear.
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believe that in our symmetric cases the reported episode of
SHL are likely to have recovered completely or almost
completely and the residual symmetrical hearing loss is the
result of both age- and FD-related effects. If this assumption
is correct, we estimate a rate of spontaneous recovery of
73%, which is of the same order of magnitude as seen in
SSNHL in the general population.
Using data from a general population [13], the expected
incidence of SHL in a normal population of the same age
and sex distribution as the FOS population over the period
studied is 3·1 in total, compared to the 32 that we observed
in total (23 males, 9 females). This corresponds to a Stand-
ardized Incidence Ratio (observed/expected) of 10·5 (95%
confidence interval: 7·2–14·8; 
 
P <
 
 0·001). This would cor-
respond to an expected proportion of patients experiencing
SHL of 0·96%.
 
Discussion
 
Using the FOS database, we have analysed 86 audiograms
from a wide age range of patients with FD. This is the largest
survey of hearing function in FD. Because audiometric data
in the FOS registry have been collected from 10 different
centres in 7 countries its validity could be criticized. These
centres have not been evaluated regarding systematic
audiographic differences; however, given that ISO 8253–1
guarantees a high degree of comparability we are confident
that the results are valid. Comparing our data with ISO
7029, it is also valid as ISO 8253 has been applied in both
populations.
A general problem in audiometry is how to define ‘normal’
hearing. We have used various classifications (ISO 7029,
WHO-ICIDH and audiometric configuration) throughout
the literature. These gave different results, which highlight
the difference between hearing loss in relation to a control
population, which might be of no clinical relevance for the
patient, and hearing impairment, which is age-independent
and has by definition a clinical impact on the patient.
Audiometric configuration is age-independent but does not
contain information on clinical relevance so it cannot be
compared directly with the other two classifications.
We found that hearing was worse in Fabry patients than
in the general population. Hearing thresholds were con-
sistently above the median value of an age-matched control
group (ISO 7029) even where the audiograms may be
classified as ‘normal’. However, in only 16% of patients,
hearing loss led to a significant impairment of hearing as
defined by the WHO. Hearing loss was usually slowly
progressive and symmetrical in both ears, but the incidence
of SHL was significantly increased in comparison with the
general population. Hearing seems to be affected at all fre-
quencies, especially in the low-frequency range, where the
proportion of thresholds above the 95th centile of the general
population is a little higher. However, as hearing in the normal
population also declines with age, predominantly in the high
frequencies, this might be the reason why Fabry patients
seem relatively less impaired at higher frequencies. The
equal percentages of flat (24%) audiographic configuration
and high frequency loss (12% gently and 7% steeply
sloping) also do not point towards a significant preference
of Fabry-specific damage to high frequencies. Other factors
like concomitant diseases might also be responsible for
hearing loss in some of the Fabry patients. We did not analyse
such factors in our study population for several reasons.
First, there is no information on the distribution of such
factors in the ISO 7029 population. This makes a comparison
impossible. Second, we know of no reports that describe an
association of FD with other diseases potentially affecting
hearing. Third, Fabry-specific lesions in other organs such
as the kidneys could affect hearing indirectly. Nevertheless,
such an effect must also be attributed to FD and would not
constitute a separate factor.
Our findings differ from previous reports by Germain
 
et al
 
. [5] and Hajioff 
 
et al
 
. [6] who found a predominantly
high-frequency hearing loss. With regard to results of Hajioff
 
et al
 
. [6] this may be due to the fact that they did not correct
for non-specific age-related effects. After correction for this
non-specific age-related hearing loss, our data show an addi-
tional deterioration in all frequencies that we believe to be
specific to FD. This is consistent with a pathophysiological
hypothesis of a progressive degenerative process, which is
supported by the findings of Schachern 
 
et al
 
. [1]. Taking into
account Schuknecht’s classification [14–16], the pattern in
Fabry patients closely resembles a mixed strial and sensory
type of presbyacusis. Given that the sensory type is purely
age-related, the distorted vessels in the stria vascularis,
presumably caused by Gb3 accumulation in the vascular
epithelium, could be the main causal factor in FD-related
hearing impairment. The fact that this strial type hearing
loss is also age-dependent is not surprising considering that
accumulation of Gb3 is progressive. Auditory brainstem
response (ABR) data have not been analysed in the FOS
database, as only sporadic reports are available. Never-
theless, ABR have been performed in other studies [4,5],
which found no cases of retrocochlear hearing loss. We are
confident that, in at least the vast majority of Fabry patients,
the origin of hearing loss is cochlear.
Cochlear hydrops seems not to play a role in FD, as we
detected only two ears with, respectively, a low-frequency
hearing loss and a U-shaped audiogram. Moreover,
Ménière-like symptoms are neither described in previous
reports nor suspected from our medical questionnaires.
This is also supported by a previous study [4], showing that
cochlear and vestibular involvement of the inner ear in
Fabry patients do not occur in parallel, as is commonly seen
in Ménière disease.
In the FOS database, 5·6% of patients reported episodes
of sudden hearing loss, and men appeared to be affected
2·3 times more often than women. This is much less frequent
than the 32% reported by Germain 
 
et al
 
. [5] and the 35·7%
found by Conti and Sergi [4] but is still significantly higher
than the 1% expected in the general population. The risk
of sudden hearing loss in our Fabry population is about 10-
fold greater than in the normal population. As our data on
sudden hearing loss have not been confirmed by clinical
examination and audiometry around the time of the
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suspected SSNHL, they must be interpreted with caution.
Self-reported episodes of sudden hearing loss can for example
also be caused by middle ear effusion or an ear plug. Keeping
that in mind we believe that our assumption is more likely
to be an overestimation than an underestimation of possible
SSNHL. Therefore, it seems justified to question the very
high incidence of SHL in Fabry patients reported previously
[4,5]. Better estimates will result from ongoing investigations
within FOS.
The increased incidence of SSNHL in Fabry patients and
the increased number of patients with recurrent episodes of
SSNHL could be interpreted as the result of repeated
microvascular infarcts from stenosis or occlusion of distorted
small vessels caused by thickening of endothelial and smooth
muscle cells. In addition, possible hypercoagulability in
Fabry patients [17] might also contribute to a reduced
blood supply to the inner ear.
In conclusion, hearing loss is very common in FD, even
though a clinically significant impairment was found in a
relatively small percentage of patients. Almost all hearing
thresholds were worse than the general population median
and roughly half were worse than the 95th centile. All
frequencies, mostly in the low-frequency range, deviated
significantly from the normal age-matched population. Men
were affected more severely than women. Episodes of
sudden hearing loss also appeared to occur more frequently
than in the general population and more frequently in men
than in women. Audiometric and pathological patterns
resembled those of normal age-related deterioration of
hearing and Fabry-specific strial-type degeneration.
A careful audiological evaluation should be part of the
diagnostic assessment and follow-up of patients affected by
or treated for FD.
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